An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Chia-Chi Lin, MD
National Taiwan University Hospital
Principal Investigator - Nashat Y. Gabrail, MD
Gabrail Cancer Center Research
Principal Investigator - Sharad Ghamande, MD
Augusta University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- National Taiwan University Hospital
Taipei, Taiwan, Taiwan
- Georgia Regents University- Cancer Center
Augusta, Georgia, United States
- Gabrail Cancer Center Research
Canton, Ohio, United States
- Gabrail Cancer Center Research
Dover, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2012
- Primary completion
- 30 Apr 2014
- Completion
- 30 Apr 2014
- Last update posted
- 2 Sept 2016
- Registered enrollment
- 11
- Registry id
- NCT01678690
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.